Another potential therapeutic target for gastric cancer treatment is the GCN2-eIF2α-ATF4-xCT pathway, which is activated by ROS and constitutes a signaling cascade that amplifies resistance to cisplatin via the induction of mitochondrial dysfunction (Wang et al., 2016). This evidence concerns the gene SLC7A11 and gastric cancer.